Humana Inc. (HUM) was the largest detractor in Pzena’s Q1 2026 portfolio, underperforming the Russell 1000 Value Index amid sector weakness.
Humana Inc. (HUM) weighed heavily on Pzena Investment Management’s Focused Value Strategy in Q1 2026, as the Medicare Advantage insurer emerged as the largest individual detractor. The portfolio returned -4.7% net for the quarter, lagging the Russell 1000 Value Index’s 2.1% gain, with healthcare, financials, and technology sectors driving underperformance.
The stock closed at $360.72 on June 22, 2026, reflecting a 19.57% one-month return and a 51.06% gain over the past year. Despite the quarterly setback, Humana maintains a market capitalization of $43.31 billion, with energy stocks offsetting broader market volatility during the period.
Pzena noted that while short-term challenges persisted, the current environment presents long-term opportunities for value-focused strategies.